LABHealthcare · Medical DevicesThe 1 Wall Street analysts covering Standard BioTools, Inc. hold a median 12-month price target of $1.35 — +101.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Standard BioTools, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (65): Smaller than most of the companies we track.
Value (16): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LAB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +101.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2025 | TD Cowen | Maintains | Hold | $1.55 → $1.35 |
| 5 Nov 2025 | TD Cowen | Maintains | Hold | — |
| 27 Feb 2025 | Keybanc | Downgrade | Sector Weight | — |
| 31 Oct 2024 | TD Cowen | Maintains | Buy | — |
| 1 Aug 2024 | TD Cowen | Maintains | Buy | — |
| 16 Apr 2024 | TD Cowen | Initiates | Buy | — |
| 4 Apr 2024 | Jefferies | Initiates | Buy | — |
| 12 July 2023 | Keybanc | Initiates | Overweight | — |
| 27 Aug 2020 | UBS | Maintains | Buy | — |
| 10 Aug 2020 | UBS | Maintains | Buy | — |
| 6 Nov 2019 | Janney Montgomery Scott | Downgrade | Neutral | — |
| 18 Oct 2019 | UBS | Upgrade | Buy | — |
| 15 Mar 2019 | UBS | Initiates | Neutral | — |
| 14 Mar 2019 | BTIG | Initiates | Buy | — |
| 3 Jan 2019 | Janney Montgomery Scott | Upgrade | Buy | — |
| 2 Nov 2018 | Piper Sandler | Upgrade | Overweight | — |
| 5 Feb 2016 | Deutsche Bank | Maintains | Buy | — |
| 5 Feb 2016 | Mizuho | Upgrade | Buy | — |
| 20 Jan 2016 | Cowen & Co. | Downgrade | Market Perform | — |
| 6 Jan 2016 | Avondale Partners | Initiates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LAB appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 42% of US stocks
Cheaper than 86% of US stocks
Cheaper than 55% of US stocks
Higher than 18% of US stocks
Higher than 28% of US stocks
Higher than 65% of US stocks
Higher than 18% of US stocks
Higher than 99% of US stocks
Higher than 35% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Standard BioTools, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Standard BioTools Inc. announced its financial results for the quarter ended June 30, 2026, in a press release dated August 5, 2026. The company disclosed the results for the second quarter of 2026.
Why it matters — LAB watchers rely on these quarterly results to gauge the company's recent financial performance and track its ongoing progress.
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio, while Illumina will buy out contingent payments, both moves intended to advance Standard BioTools' merger with Treeline Biosciences.
Why it matters — LAB watchers would care because these transactions streamline the company's structure and remove financial contingencies that could affect the completion of the merger with Treeline Biosciences.
The 1 Wall Street analysts covering Standard BioTools, Inc. have a median 12-month price target of $1.35, with estimates ranging from $1.35 to $1.35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Standard BioTools, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Standard BioTools, Inc. 36 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Standard BioTools, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (65 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +101.8% from the last close, and Ticker Nerd's factor model ranks Standard BioTools, Inc. 36 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Standard BioTools, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LAB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.35 to $1.35 over the next 12 months.
Standard BioTools, Inc. returned -44.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Standard Biotools Inc. is a leading developer and provider of innovative life sciences tools and solutions.
The most recent item we track (GlobeNewsWire, 5 Aug 2026): "Standard BioTools Reports Second Quarter 2026 Financial Results". Standard BioTools Inc. announced its financial results for the quarter ended June 30, 2026, in a press release dated August 5, 2026. The company disclosed the results for the second quarter of 2026.
Standard Biotools Inc. is a leading developer and provider of innovative life sciences tools and solutions. This company focuses on empowering researchers by delivering precision instruments and systems essential for high-throughput DNA sequencing, protein analysis, and molecular diagnostics. With a commitment to advancing healthcare and scientific discovery, Standard Biotools provides critical support to industries such as biotechnology, pharmaceuticals, and academic research institutions. Their cutting-edge platforms facilitate more effective and efficient data analysis, enabling breakthroughs in personalized medicine and disease understanding. Headquartered in the United States, Standard Biotools Inc. plays a vital role in the life sciences sector, frequently collaborating with research entities to propel forward the capabilities of modern biological technology. This company's contributions are crucial in addressing global health challenges and paving the way for future innovations in the scientific community.
CEO Dr. Michael Egholm Ph.D. · 385 employees · United States · https://www.standardbio.com